SK Capital Partners Invests in Halo Pharmaceutical
SK Capital Partners announced that it completed a strategic investment in Halo Pharmaceutical.
SK Capital Partners announced on Jan. 6, 2015 that it completed a controlling strategic growth investment in Halo Pharmaceutical. SK Capital Partners is a private investment firm with a focus on specialty materials, chemicals, and healthcare. Halo-a technology-focused contract development and manufacturing organization with a specialty in solid, semi-solid, and liquid dosage forms, especially controlled substances-is the sixth platform company for SK Capital Partners Fund III.
“As continuing owners of a significant share in the business, we are excited to partner with an industry-focused investor who can provide capital and resources to further improve our business and support our growth plans as we build our business … By having SK Capital as our partner, Halo will have the resources to acquire strategic assets that will increase our dosage forms offerings, formulation technologies, and enable superior customer service as a one-stop source for formulation development through commercialization,” said Mohd Asif, co-founder of Halo Pharmaceutical, in a press release.
Source: SK Capital Partners
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
